Comparative effectiveness of sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised patients on kidney replacement therapy: observational cohort study using the OpenSAFELY-UKRR linked platform and SRR database [PDF]
, 2022 Background: Patients on kidney replacement therapy (KRT; dialysis and kidney transplantation) are at the highest risk of severe outcomes from COVID-19.
core +4 more sources
Use of molnupiravir:A Danish nationwide drug utilization study [PDF]
, 2023 Purpose: To describe utilization patterns, characteristics of users and prescribers of the new oral antiviral medication, molnupiravir, indicated for mild-to-moderate COVID-19.
Hallas, Jesper +6 more
core +1 more source
Molnupiravir Inhibits Porcine Epidemic Diarrhea Virus Infection In Vitro
Viruses, 2023 Porcine epidemic diarrhea virus (PEDV) is a swine coronavirus that is highly infectious and prone to variation. Vaccines derived from traditional PEDV strains provide less protection against PEDV-variant strains. Furthermore; there is a complex diversity
Zi-Xin Huang +3 more
doaj +1 more source
Molnupiravir and risk of hospital admission or death in adults with Covid-19: Emulation of a randomized target trial using electronic health records [PDF]
, 2023 OBJECTIVE: To emulate a randomized target trial to estimate the association between the antiviral drug molnupiravir and hospital admission or death in adults with SARS-CoV-2 infection in the community during the omicron predominant era who were at high ...
Al-Aly, Ziyad, Bowe, Benjamin, Xie, Yan
core +2 more sources
Molnupiravir for treating COVID-19 [PDF]
Cochrane Database of Systematic Reviews, 2022 Objectives\ud This is a protocol for a Cochrane Review (intervention). The objectives are as follows:\ud \ud To assess the effects of molnupiravir in people with confirmed SARS‐CoV‐2 infection and mild‐to‐moderate symptoms, with or without risk factors for severe disease.
Ochodo, Eleanor +7 more
openaire +1 more source
Infectious Diseases and Therapy, 2023 Introduction Molnupiravir is an oral antiviral drug that received special approval for emergency use in Japan on December 24 2021 for infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Masahiro Kimata +4 more
doaj +1 more source
Frontiers in Pharmacology, 2022 Background: The rapid worldwide spread of the Omicron variant of SARS-CoV-2 has unleashed a new wave of COVID-19 outbreaks. The efficacy of molnupiravir, an approved drug, is still unknown in patients infected with the Omicron variant.Objective ...
Rongrong Zou +15 more
doaj +1 more source
Molnupiravir and risk of post-acute sequelae of covid-19: Cohort study [PDF]
, 2023 OBJECTIVE: To examine whether treatment with the antiviral agent molnupiravir during the first five days of SARS-CoV-2 infection is associated with reduced risk of post-acute adverse health outcomes. DESIGN: Cohort study.
Al-Aly, Ziyad, Choi, Taeyoung, Xie, Yan
core +2 more sources
Frontiers in Pharmacology, 2023 Introduction: Randomized, controlled trials of molnupiravir in real-world use during the Omicron wave are scarce. The frequency of hospitalization and death is low, so further research is needed to confirm the virological efficacy of molnupiravir.Methods:
Yayun Liu +9 more
doaj +1 more source
The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In Vitro [PDF]
, 2022 Introduction: The development of effective vaccines has partially mitigated the trend of the SARS-CoV-2 pandemic; however, the need for orally administered antiviral drugs persists.
Bastianelli, Sabrina +12 more
core +1 more source